Albert Bourla on 2024 guidance
From Pfizer CEO doubles down on 2024 guidance, talks Seagen buy · · Yahoo Finance
“I do think so because the covid revenues have been significantly deris right now is not only how much is going to be the utilization of the product but it is basically that we have gun into commercial model we have renegotiated multi-billion dollar agreements with multiple governments in the world to resolve the stock issues so I think people can predict the covid business very well but the non-co business also it is the one that I think did very well in last year we had the 7% growth and we gave a guidance of 8 to 10% growth for the non-id business going forward so we are very very optimistic that we will make this guidance and that's why I reaffirmed it”
On , Albert Bourla, Chairman of the Board & Chief Executive Officer at Pfizer Inc, spoke about 2024 guidance during Pfizer CEO doubles down on 2024 guidance, talks Seagen buy on Yahoo Finance.
About Albert Bourla
Albert Bourla, chairman and CEO of Pfizer, said on the company’s first-quarter 2026 earnings call that the company’s strong performance reflected “disciplined execution” and that new and acquired products grew 22% in the quarter. He stated that Pfizer does not plan a large merger in the near term, describing the next few years as a time to “execute on AI transformation” rather than pursue a mega-merger. Bourla also highlighted recent patent settlements for Vyndamax, which he said give the company confidence it will enter a period of high single-digit revenue growth starting in 2029. He noted that Pfizer invested nearly $80 billion in recent years to acquire molecules and pipelines to offset upcoming patent losses. In multiple interviews, Bourla discussed the rise of China’s pharmaceutical sector, arguing that the U.S. should focus on improving its own innovation rather than trying to slow China’s progress. He described China’s scientific capabilities as having a “meteoric rise” and said that by the end of the decade, eight of the world’s top ten universities based on peer-reviewed publications were Chinese. Bourla expressed optimism about artificial intelligence, calling it “transformative” and predicting it will contribute to a “scientific renaissance” in medicine. He also commented on U.S. health policy, saying he was encouraged by recent statements from Trump administration officials about modernizing the FDA and accelerating drug development, though he said he had not yet seen practical effects. Bourla described his increased time in Washington as necessary because health care has become “extremely politicized” and because governments are major customers for Pfizer.